Court Kills Rule Aimed At Undermining Copay Coupons

By John Wilkerson / May 17, 2022 at 4:50 PM
A federal judge ruled that CMS cannot make brand drug companies subtract the financial assistance they offer patients in the commercial market from the so-called best prices they must offer Medicaid. The ruling kills a Trump-era regulation that called for making drug companies ensure patients receive the entire benefit of financial assistance, and if they can’t, drug companies must subtract the value of those copay coupons from the prices they charge Medicaid. That financial assistance measure was supposed to take...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.